The reason why peptides might soon become illegal to purchase through even compounding pharmacies, let alone gray market, is because Lilly would like to protect the domain over that patent." Andrew Huberman $36.5 billion in 2025 alone
Frequently asked questions Medicares $50/month GLP-1 demonstration program is expected to launch in July 2026, with the full BALANCE model starting in January 2027
Deibert says
The study reported similar rate of cesarean delivery (range: 23%52%) and infant birth weights (MD: 93 g, 95% CI: 191 to 5 g), with no significant difference in maternal glycemic control between the treatments.[176] Furthermore, a systemic review and meta-analysis reported no significant difference in terms of glycemic control or pregnancy outcomes between GLIB and insulin when used during pregnancy.[177] Moreover, in a meta-analysis, no significant difference was observed in the rate of neonatal major abnormality or neonatal death among women treated with GLIB-metformin compared with nonexposed women during first trimester
When used together, there is a theoretical possibility of additive effects on blood glucose levels
Eur J Drug Metab Pharmacokinet